Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 160 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Crohn's Disease, Active Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329
View directory record Official record
Conditions
Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions
Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 2 Interventional

Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

NCT00101946
View directory record Official record
Conditions
Crohn's Disease
Interventions
683699
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Garden Grove, California • Roseville, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients

NCT01576120
View directory record Official record
Conditions
Crohn's Disease
Interventions
bowel prep regimen first boost 6 oz. and second boost 3 oz., bowel prep regimen first boost 3 oz. and second boost 6 oz.
Other
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Beavercreek, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Jul 22, 2026, 8:17 PM EDT
Recruiting Phase 3 Interventional

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
Vedolizumab IV
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

NCT00160524
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

NCT02531113
View directory record Official record
Conditions
Crohn's Disease
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Tucson, Arizona • Largo, Florida • Palmetto Bay, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jul 22, 2026, 8:17 PM EDT
Active, not recruiting No phase listed Observational

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

NCT02130362
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
45
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Jul 22, 2026, 8:17 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease

NCT04827368
View directory record Official record
Conditions
IBD, Crohn Disease, Ulcerative Colitis
Interventions
Breath Test
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Jul 22, 2026, 8:17 PM EDT
Terminated Phase 2 Interventional

VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease

NCT05688852
View directory record Official record
Conditions
Crohn Disease
Interventions
VTX958, VTX958 Placebo
Drug
Lead sponsor
Ventyx Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Garden Grove, California • Lancaster, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

NCT01714726
View directory record Official record
Conditions
Crohn's Disease
Interventions
MEDI2070, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
26
States / cities
Encinitas, California • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Jul 22, 2026, 8:17 PM EDT
Not listed Not applicable Interventional

Diet as Essential Therapy (DIET) for Inflammatory Bowel Disease

NCT03012542
View directory record Official record
Conditions
Crohn Disease
Interventions
Diet 1, Diet 2
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Not applicable Interventional Results available

Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.

NCT03241368
View directory record Official record
Conditions
Crohn Disease
Interventions
Capsule Endoscopy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jul 22, 2026, 8:17 PM EDT
Not listed Phase 3 Interventional

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

NCT01817972
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol, Azathioprine
Biological · Drug
Lead sponsor
Gastroenterology Research of America
Other
Eligibility
18 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Jul 22, 2026, 8:17 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Placebo, MORF-057
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
25
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 8:17 PM EDT
Recruiting Phase 3 Interventional

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

NCT07577843
View directory record Official record
Conditions
Crohn Disease
Interventions
JNJ-78934804, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Anaheim, California • Chula Vista, California • Colorado Springs, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 8:17 PM EDT
Terminated Phase 3 Interventional Results available

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

NCT03467958
View directory record Official record
Conditions
Crohn Disease
Interventions
Ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
190
States / cities
Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 142 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

NCT00032799
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 2 Interventional

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

NCT01751152
View directory record Official record
Conditions
Inflammation, Crohn's Disease
Interventions
NNC0114-0006, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
9
States / cities
Tucson, Arizona • Little Rock, Arkansas • Laguna Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

NCT02425111
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
22
States / cities
La Jolla, California • Hamden, Connecticut • Gainesville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Jul 22, 2026, 8:17 PM EDT
Active, not recruiting Phase 2 Interventional

Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

NCT05910528
View directory record Official record
Conditions
Crohns Disease
Interventions
Afimkibart
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Dothan, Alabama • Hamden, Connecticut • Kissimmee, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 22, 2026, 8:17 PM EDT
Not listed Phase 4 Interventional

Does Clinical Response Correlate With Serum Certolizumab Levels?

NCT02597829
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol
Drug
Lead sponsor
Shafran Gastroenterology Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Jul 22, 2026, 8:17 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

NCT02574637
View directory record Official record
Conditions
Crohn's Disease
Interventions
Brazikumab IV Infusion, Brazikumab SC Injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Phoenix, Arizona • Lone Tree, Colorado • Clearwater, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Jul 22, 2026, 8:17 PM EDT
Recruiting Phase 3 Interventional

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931
View directory record Official record
Conditions
Crohn's Disease
Interventions
Duvakitug, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 80 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
94
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

NCT01290042
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
AMG 181, Placebo for AMG 181
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
5
States / cities
Glendale, California • Bridgeport, Connecticut • Danbury, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Jul 22, 2026, 8:17 PM EDT